Abstract 2649: Development of an antibody-drug conjugate targeting TIM-1 for the treatment of ovarian and renal cell carcinoma

@inproceedings{Thomas2014Abstract2D,
  title={Abstract 2649: Development of an antibody-drug conjugate targeting TIM-1 for the treatment of ovarian and renal cell carcinoma},
  author={Lawrence J. Thomas and Laura Vitale and Thomas O’Neill and Ree Y. Dolnick and Paul Wallace and Hans Minderman and Lauren E. Gergel and Eric Forsberg and James M. Boyer and James R. Storey and Russell A. Hammond and Jennifer Widger and Karuna Sundarapandiyan and Andrea Crocker and Henry Marsh and Tibor Keler},
  year={2014}
}
Proceedings: AACR Annual Meeting 2014; April 5-9, 2014; San Diego, CA T cell immunoglobulin and mucin domain 1 (TIM-1) is a type I transmembrane protein that was originally described as kidney injury molecule 1 (KIM-1) due to its elevated expression in kidney and urine after renal injury. Tim-1 expression is also upregulated in several human cancers, most notably in renal cell and ovarian carcinomas, but has very restricted expression in healthy tissues thus representing a promising target for… CONTINUE READING